Clinical trial
Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis
Name
RD.03.SPR.29106
Description
The main objective is to compare efficacy, in terms of antifungal activity of Loceryl Nail Lacquer associated with a Cosmetic Varnish and Loceryl Nail Lacquer alone, in the treatment of mild to moderate toenail Distal Subungual Onychomycosis.
The second objective of this study will be photographic follow-up of clinical improvement and cure after the initial treatment period of 12 weeks, for 15 additional months.
Trial arms
Trial start
2014-02-01
Estimated PCD
2016-01-01
Trial end
2016-01-01
Status
Completed
Phase
Early phase I
Treatment
Loceryl NL + Cosmetic varnish
Loceryl NL + Cosmetic varnish once/week for 12 weeks
Arms:
Investigator blinded Loceryl NL+ Cosmetic varnish
Loceryl NL 12 weeks
Loceryl NL once/week for 12 weeks
Arms:
Investigator blinded Loceryl NL alone
Loceryl NL 15 months
Loceryl once/week for additional 15 months
Arms:
Investigator blinded Loceryl NL alone, Investigator blinded Loceryl NL+ Cosmetic varnish
Size
50
Primary endpoint
Measurement of Antifungal Activity of Loceryl Nail Lacquer
Week 12
Eligibility criteria
Inclusion Criteria:
* Subjects with a mild to moderate Distal Subungual Onychomycosis (DSO) on at least 1 great toenail chosen as a Target nail
* Subjects must have maximum of 50% of nail distal edge involved
* Subjects with positive mycological results (direct microscopy and culture) of the Target nail for dermatophytes or Yeast (including Candida) at Screening
Exclusion Criteria:
* Subjects with clinically important abnormal physical findings at the Screening/Baseline visit
* Subjects with Lichen planus, eczema, psoriasis, or other abnormalities of the nail unit
* Subjects with known immunodeficiencies, radiation therapy, immune suppressive drugs
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'Only 12 first weeks of treatment with Loceryl NL and/or Loceryl alone were investigator masked and randomized.\n\n15 months of treatment with Loceryl NL alone had an open study design', 'whoMasked': ['INVESTIGATOR']}}, 'enrollmentInfo': {'count': 50, 'type': 'ACTUAL'}}
Updated at
2023-01-19
1 organization
3 products
1 indication
Indication
Foot DermatosesOrganization
Galderma R&DProduct
LocerylProduct
Loceryl NL